Arcturus Therapeutics Holdings Overview
Arcturus Therapeutics Holdings Target Price
Arcturus Therapeutics Holdings target price — quarterly history, peer benchmarks, and growth trends.
Get informed when a big investor buys or sells
+ FollowShare Price
$7.6
Average Target Price
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-03-04 | Piper SandlerYasmeen Rahimi | $25 |  228.9% upside |  |
| 2026-01-22 | Roth Capital | $20 | 163.2% upside | |
| 2025-08-22 | Leerink PartnersLili Nsongo | $54 | 610.5% upside | |
| 2025-05-28 | ScotiabankGreg Harrison | $32 | 321.1% upside | |
| 2025-03-10 | BTIGThomas Shrader | $48 | 531.6% upside | |
| 2024-11-11 | Canaccord GenuityWhitney Ijem | $10.58 | 39.2% upside | |
| 2024-08-06 | Canaccord GenuityWhitney Ijem | $10.3 | 35.5% upside | |
| 2024-07-02 | H.C. WainwrightEd Arce | $8.58 | 12.9% upside | |
| 2024-05-31 | Piper SandlerYasmeen Rahimi | $20.02 | 163.4% upside | |
| 2024-05-10 | Canaccord GenuityWhitney Ijem | $12.3 | 61.8% upside | |
| 2024-03-19 | LaidlawYale Jen | $11.3 | 48.7% upside | |
| 2022-11-02 | BarclaysGena Wang | $25 | 228.9% upside | |
| 2022-05-11 | Goldman Sachs | $14 | 84.2% upside | |
| 2021-11-09 | Goldman SachsMadhu Kumar | $30 | 294.7% upside | |